Skip to content
DataLookout
Menu

FUTURENCT07257718

A Phase II, Prospective, Single-center Study of FAPI PET Imaging and Liquid Biopsy in Bladder Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Sep 2026 to Nov 2026 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 207 words
    • Interventions modified
    • Secondary endpoint revised
    • Study title shortened, about 5 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Assessing the diagnostic accuracy of FAPI PET and liquid biopsy in bladder cancer staging vs conventional imaging
Timeframe: 1 day

Secondary (1)

Assessing the disease burden of FAPI PET vs liquid biopsy in bladder cancer staging

Arms and interventions

BC patients eligible for radical cystectomyExperimental

BC patients treated with radical cystectomy ± neoadjuvant therapy

BC patients treated with systemic therapyExperimental

patients eligible for conservative treatment

Diagnostic tests: FAPI PET/CT with [68Ga]Ga-BED003, ctDNA/utDNA liquid biopsy